Access cutting-edge acute ischemic stroke treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access acute ischemic stroke specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute ischemic stroke treatment provided free
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 156 patients are planned in this study.
Sponsor: Basking Biosciences, Inc.
Check if you qualify for this acute ischemic stroke clinical trial in San Francisco, CA
If you're searching for acute ischemic stroke treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.